PolyPid Investor Day 2026 & KOL Event
Review the key takeaways and the transcript of this earnings call.
Transcript
Preview the first fifteen paragraphs, organized by speaker.
Please be advised that today's conference is being recorded. I would now like to hand the conference over to your speaker today, Yehuda Leibler.
Please go ahead. Good morning, everyone, and welcome to PolyPid's Investor Day.
My name is Yehuda Leibler from Arx Investor Relations. With me on the call today, you have Dikla Czaczkes Akselbrad, Chief Executive Officer of PolyPid, Ori Warshavsky, Chief Operating Officer, U.S. of PolyPid, our guest, Dr. Warren Joseph, and joining us on the live Q&A will be Jonny Missulawin, Chief Financial Officer of PolyPid. Earlier this morning, PolyPid issued a press release outlining today's announcements. That release and the presentation you'll see today are available on the Investors section of PolyPid's website. The prepared remarks were recorded ahead of today's event, and the Q&A session you'll see at the end is live. Before we begin, I'd like to remind you that during today's event, management and our guest will make forward-looking statements within the meaning of the federal securities laws.
For example, management is making forward-looking statements when it discusses the U.S. Food and Drug Administration's, or FDA's, review of the new drug application, or NDA, for D-PLEX100. That includes the priority review designation and the Prescription Drug User Fee Act, or PDUFA, goal date of November 28, 2026. Forward-looking statements also include possible label expansion beyond colorectal surgery, the FDA pre-approval inspection of the company's manufacturing facility, the potential approval of D-PLEX100, and the expected commercial launch of D-PLEX100 by Azurity Pharmaceuticals in the United States in 2027. They also include the company's exclusive commercialization partnership with Azurity for the United States and Canada. That covers the partnership's economic structure, potential milestone payments, tiered royalties, and transfer price, and the joint development activities, as well as label expansion programs contemplated under that agreement.
The forward-looking statements on this call also cover potential reimbursement for D-PLEX100, including the New Technology Add-On Payment, or NTAP, status. Additional forward-looking statements include the European Medicines Agency's, or EMA's, review of the Marketing Authorisation Application, or MAA, for D-PLEX100, and the anticipated timing of that review. They also include the company's plans for commercialization of D-PLEX100 in Europe and other territories following the reversion of European rights from ADVANZ PHARMA, including potential partnerships. Forward-looking statements also include the design, development, planned regulatory pathway, and anticipated timing of the investigational new drug application and clinical trials of PD01B, as well as its potential benefits. Finally, they include the company's Kynatrix technology and other pipeline programs, including its long-acting metabolic program, and the company's growth strategy and expected milestones through 2030.
Forward-looking statements are subject to numerous risks and uncertainties, many of which are beyond the company's control. These include the risks described from time to time in the company's filings with the Securities and Exchange Commission. Accordingly, you should not place undue reliance on these statements. I encourage you to review the company's filings with the SEC, including its annual report on Form 20-F, filed on February 25, 2026. PolyPid disclaims any intention or obligation, except as required by law, to update or revise any forward-looking statements. PD01B is an investigational product candidate and has not been approved by the FDA or any other regulatory authority. Dr. Joseph's views are his own. This event contains time-sensitive information and speaks only as of today, October 28, 2026. With that, I'd like to turn the event over to Dikla Czaczkes Akselbrad, CEO of PolyPid.
Dikla? Thank you, Yehuda, and good afternoon, everyone.
It is great to be here. We are now exactly one month away from our PDUFA date, so it is obviously a very exciting and important time for PolyPid. This is also our first event since we signed our U.S. partnership, other than our quarterly call. For a long time, one of the questions I was asked more often by investors was: When are you going to sign a U.S. partnership, and what will that partnership look like? I think we can now say that this question has been fully answered. Today, I would like to move the discussion forward and focus on the next question. What will PolyPid look like in 2030?
I will start with a very brief recap of where we are today, and then I will focus on three key growth levers that we believe can drive PolyPid through 2030. We will also introduce our next product candidate, PD01B, and its potential role in diabetic foot infection. Ori will take you through the program, and then we will hear from Dr. Warren Joseph, who will provide his perspective on the significant unmet need in diabetic foot infection. Let's start with where we are today, because the last six months have been a period of significant progress for the company. In July, we signed an exclusive licensing agreement with Azurity Pharma covering U.S. and Canada. Under the agreement, we received a $30 million upfront payment, and we are eligible for an additional over $290 million in development, regulatory, and sales milestones.
We are also entitled to tiered royalties on net sales ranging from the mid-teens to mid-20s, and we have a prenegotiated transfer price for each vial that we will manufacture and supply to Azurity Pharma. Another important component of our agreement is label expansion. Azurity Pharma will fund the clinical development for label expansion. Since signing the agreement, our working relationship with Azurity has been excellent. Azurity is building out its sales force, national accounts, market access, and medical affairs team ahead of potential launch in 2027 with a hospital footprint that reaches more than 1,700 leading U.S. hospitals and academic centers. Our teams meet regularly across medical, regulatory, supply chain, and commercial functions, and we are working closely together to prepare for day one of launch.
On the regulatory front, the NDA that we submitted earlier this year is under priority review with a target PDUFA date of November 28, 2026, and all scheduled FDA interactions on track and aligned with D-PLEX100's PDUFA goal date. In addition, an application for a New Technology Add-on Payment, or NTAP, was submitted to CMS in October this year, with a decision expected next August. If approved, NTAP would provide additional hospital reimbursement for D-PLEX100 in the inpatient setting. In Europe, we submitted our Marketing Authorization Application to the EMA in September, and it was validated at the end of that month. D-PLEX100 is now under formal review by the EMA. Earlier this month, we regained full European commercial right to D-PLEX100, which I will come back to in a moment.
The bottom line of this, over the past six months, we told you what we would do, and we did it. So why hold this event now? From day one, we built PolyPid to be a platform company. D-PLEX100 was always meant to be our first product, not our only one. Our technology delivers a drug at high concentration over a controlled period of time, and the value of that goes well beyond colorectal surgery and well beyond surgical site infections. So why now? With D-PLEX100 approaching potential approval and with a commercial committed partner funding the U.S. launch and label expansion, we are now in a position to move forward on several front at once. D-PLEX100 has demonstrated what our technology can do. Now we are putting the platform to work.
We think about value creation over the next several years through three key levers, spanning from near, mid, and long-term. First, maximize the potential of D-PLEX100 throughout our U.S. partnership, including label expansion beyond colorectal surgery. Second, bringing D-PLEX100 to additional territories, starting with Europe. Third, build a pipeline based on our technology platform, beginning with PD01B. Our base case is that D-PLEX100, subject to approval, will be approved for patient undergoing colorectal surgery with large incision. That is the patient population covered by our initial U.S. application. But surgical site infection isn't only a colorectal problem. It is a surgical problem, and it carries a significant burden, both clinical and economically, across many different surgeries. Our first step is to expand into broader abdominal surgery, including GI procedures and hysterectomies.
This represent around 4 million surgeries each year in the U.S., with close to half of them being open procedures. We plan to initiate discussions with the FDA in the fourth quarter of this year. Beyond that, we see additional opportunities in soft tissue surgeries such as breast reconstruction and post weight loss body contouring. This is a fast-growing segment as more patient experience significant weight loss with GLP-1 therapies. These are also procedures involving very large incisions. Then there are opportunities in bone-related surgeries, including trauma and fracture fixation, as well as lumbar fusion. Importantly, under our agreement, Azurity funds the clinical development of the label expansion programs that we pursue together while PolyPid retain clinical and scientific role. This make label expansion one of the most capital-efficient growth opportunities available for us.
The product is already developed and manufactured, and it is already in the hands of a commercial partner that is funding the clinical development work. The decision on which indication to prioritize will be made jointly with Azurity following potential approval, and we will update you as those plans take shape. Our second lever is geography. In the U.S., launch is expected in 2027, subject to approval. In Canada, we plan to submit a new drug submission in 2027. With the EMA validated and under EMA review and full European right now back with PolyPid, we control our European strategy. We are evaluating how to maximize the value of D-PLEX100 in Europe, including active partnership discussions.
FULL TRANSCRIPT
Continue the full translated transcript in StockNow.
Access every statement, the English original, and speaker-by-speaker history with StockNow Pro.
View the full transcript with ProCall participants
11 people spoke on this call — only 2 are shown here.
PARTICIPANT LIST
View participant details in StockNow.
Log in to see executives and analysts, their roles, and complete speaking history.
Log in to view all participantsKeep exploring
